24
affect microtubule stability (Cioffi et al, 2011) . FKBP7, also known as FKBP23, is another molecular 25 chaperone that was previously cloned from mouse heart (Nakamura et al, 1998) . FKBP7 is located in 26 the endoplasmic reticulum and was shown to suppress the ATPase activity of the mouse ER 27 chaperone HSPA5/GRP78/Bip by its prolyl-peptidyl isomerase activity (Zhang et al, 2004; Nakamura 28 et al, 1998) . The function of the human FKBP7 has not yet been characterized and to date its role in 29 cancer has never been explored.
30
In the present study, we established four chemoresistant prostate cancer cell lines to explore 1 mechanisms of taxane resistance. A high throughput proteomic approach was used to investigate the 2 signaling pathway involving FKBP7 and its potential role in taxane resistance.
4

RESULTS
5
FKBP7 is upregulated during the progression of chemoresistant CRPC 
6
To decipher the mechanisms of taxane resistance in prostate cancer, we developed a series of four 7 isogenic parental, docetaxel-resistant (Dtx-R), and cabazitaxel-resistant (Cbx-R) cell lines 8 representative of the different types of epithelial prostate cancer cells (Fig S1) . By comparing the gene 9 expression profiles between parental and different docetaxel-resistant cells (Chauchereau et al, 2011;  10 Nakouzi et al, 2014), we generated a signature of 998 highly differentially expressed genes potentially 11 correlated with chemoresistance (Table S1 ). Following image-based high-content screening in which 12 the 593 overexpressed genes were independently targeted with 4 different siRNAs in IGR-CaP1-R100 13 cells, we identified 34 genes required for cell survival of docetaxel-resistant cells, for which at least 2 
14
siRNAs showed robust Z-score>2 for G0 cell-cycle arrest phenotype modification and cell proliferation.
15
We focused our attention on chaperone proteins responsive to stress. In particular, as already
16
reported in several solid cancers (Gifford et al, 2016; Roller & Maddalo, 2013) , the ER chaperone 17 protein HSPA5 also known as GRP78/BiP, was sorted as a candidate involved in chemoresistance in 18 our model. Considering that HSPA5 was reported to interact with the FKBP7 chaperone in a mouse 19 model (Zhang et al, 2004) , we focused on the potential role of the uncharacterized human protein
20
FKBP7 in the mechanism of taxane resistance in prostate cancer.
21
FKBP7 protein levels were higher in the four parental prostate cancer cell lines compared to the non-
22
cancerous prostate cells RWPE-1 (Fig 1A) . FKBP7 protein levels were higher in all docetaxel-and since we found more FKBP7 mRNA in the taxane-resistant cells (Fig S2) . To investigate the 26 physiological relevance of FKBP7 expression in prostate cancer, we determined FKBP7 expression by 27 immunohistochemistry using tissue microarrays containing 381 prostate cancers and benign tissues 28 obtained from radical prostatectomy or from transurethral resection (Table S2) . 
18
Consistent with what we observed in cell lines, FKBP7 was more present in different stages of
19
prostate cancers compared to benign tissues (Fig 1B) . Quantification of staining intensities showed 20 that FKBP7 levels (moderate to strong staining) were significantly higher in prostate cancer than in 1 benign tissues (Fig 1B) . We further evaluated FKBP7 expression using tissue microarrays comprising 
5
FKBP7 levels developed recurrence compared to 42% for patients with a low level of FKBP7. High 6 levels of FKBP7 were significantly associated with a shorter time to recurrence in patients (p=0.004,
7
hazard ratio for low FKBP7 staining: 0.3846) (Fig 1D) . The levels of FKBP7 during the progression to 8 lethal prostate cancer did not correspond to gene mutations in the published data from whole exome 9 sequencing in docetaxel-treated CRPC patients (Grasso et al, 2012) . Together, these results provide 10 strong evidence for a role of FKBP7 in prostate tumor cell growth and chemoresistance.
12
SiRNA-mediated knock-down of FKBP7 blocks chemoresistant cell growth and sensitizes
chemoresistant cells to taxane treatment
14
To determine whether FKBP7 could be a therapeutic target in chemoresistant prostate cancer, we 15 used two different siRNA sequences targeting FKBP7, to knock-down FKBP7 expression in all 16 chemoresistant cells. FKBP7 silencing significantly decreased chemoresistant cell growth (Fig 2A) .
17
FKBP7 silencing slightly induced apoptosis of chemoresistant cells and PARP cleavage was further 18 increased after treatment with docetaxel and cabazitaxel (Fig 2B) . These results show the importance 
3
The 25nM-resistant emerging tumor was maintained in vivo for 5 successive passages to increase the 4 tumorigenicity (Fig S3) . These tumors, called IGR-CaP1-Rvivo, did not respond to 3 successive 5 injections of docetaxel at 30mg/kg, in contrast to the parental IGR-CaP1 mouse model which 6 responded to docetaxel (Fig 3A) , and therefore constitute a new docetaxel-resistant mouse model. A 7 new cell line, called IGR-CaP1-Rvivo, was generated from the IGR-CaP1-Rvivo tumors and showed 8 chemoresistance characteristics (with IC 50 =207nM towards docetaxel) (Fig 3B, left panel) . In addition,
9
and in agreement with our results obtained in vitro and in human samples, the resistant IGR-CaP1-
10
Rvivo cell line exhibited high levels of FKBP7 (Fig 3B, right panel) . Thus, to interrogate whether
11
FKBP7 could be a therapeutic target in a docetaxel-resistant mouse model, we established two IGR-
12
CaP1-Rvivo cell lines in which FKBP7 was stably silenced with two different shRNAs. We achieved a 
22
while it weakly decreased the growth of control shRNA-transduced tumors (Fig 3C, right panel) 
1
We determined the levels of FKBP7 in various normal human cell lines of different origins (fibroblastic, 2 myoblastic, epithelial, or endothelial cells). These non-cancerous cells exhibited a high protein level of 3 FKBP7, which was even higher than the one observed in IGR-CaP1-Dtx-R cells (Fig S4A) . However,
4
contrasting with the results obtained in chemoresistant cells, we observed no effect of FKBP7 5 inhibition on cell growth and viability in non-cancerous cells (Fig S4B) , suggesting that FKBP7 could 6 have a different function in normal and in cancerous cells. FKBP7-silencing led to a decrease in eIF4G in docetaxel-resistant IGR-CaP1 while it led to an 8 increase in eIF4G in the corresponding non-cancerous RPE-1 cells (Fig 5A) . In contrast, the protein 9 level of eIF4A and eIF4E remained unchanged upon FKBP7 silencing (Fig 5A) . Of note, the level of eIF4G-silencing respectively) (Fig 5D) . In this experiment, the silencing of eIF4G was very efficient
24
( Fig S5B) and the specificity of the FKBP7-eIF4G interaction was validated (Fig S5C) .
25
Since FKBP7 interacts with eIF4G and modulates eIF4G protein levels, we next investigated the effect 26 of FKBP7 on the formation of the eIF4F complex using PLA. Docetaxel treatment led to a decrease in 27 the formation of the eIF4E-eIF4G complex in the docetaxel-sensitive IGR-CaP1 cells (Fig 5E, left   28 panel). Strikingly, but consistently with other studies showing that the formation of the eIF4E-eIF4G 29 determines the sensitivity to anti-cancer targeted therapies (Boussemart et al, 2014) , this effect was 30 13 not observed in the resistant cell line IGR-CaP1-Dtx-R (Fig 5E, left panel) . SiRNA-mediated depletion 1 of FKBP7 induced a decrease in the formation of the eIF4E-eIF4G complex upon treatment with 2 docetaxel in resistant cells (Fig 5E, right panel) . Thus, the formation of the eIF4E-eIF4G complex can 3 be inhibited by docetaxel in resistant cells only when FKBP7 is silenced. Therefore, FKBP7 which is 4 up-regulated in chemoresistant cells could maintain the eIF4F complex by directly regulating eIF4G 5 protein levels and consequently increasing its activity, leading to a hyper-activation of cap-dependent 6 translation and subsequent cell survival upon taxane treatment. Finally, FKBP7 was able to stabilize 7 the eIF4F complex formation upon taxane treatment and thus could be a novel regulator of eIF4F. 
18
The interactions were visualized as red dots and the nuclei in blue. Interaction dots were quantified (n≥ 100 cells)
19
and analyzed with the general linear model or with Wilcoxon rank test, ** p<0.01;*** p<0.001.
21
Targeting of chemoresistant prostate cancer cells with small molecule inhibitors of eIF4A
22
We looked at the structure and the function of FKBP7 to determine whether available drugs might 
26
Dtx-R cells were resistant to rapamycin compared to the breast cancer cell line MCF7 (Fig 6A) . Since 27 FKBP7 regulates eIF4F complex formation which is involved in chemoresistance, we tested inhibitors 
31
Chambers et al, 2013). Silvestrol induced a cytotoxic effect in the A375 melanoma cell line 32 (Boussemart et al, 2014) , but showed no effect on the IGR-CaP1-Dtx-R cells (Fig 6A) . This lack of 33 activity of silvestrol could be due to the fact that it is a substrate of the Pgp drug efflux pump (Gupta et 
34
al, 2011) which is highly expressed in the IGR-CaP1-Dtx-R cells (Fig S6) . In contrast, the docetaxel-
35
resistant IGR-CaP1 and 22RV1 cells were sensitive to low doses of FL3 (IC 50 =19nM and 14nM 36 respectively) and FL23 (IC50=7nM and 7nM) (Fig 6B) . Both compounds target eIF4A but are not 37 substrates of Pgp (Thuaud et al, 2009 ). The observed IC 50 for these compounds were similar to the 38 ones observed in the melanoma A375 cells (IC 50 =13 and 18nM respectively). Thus, our results showed that FL3 and FL23 were able to kill the chemoresistant cells; however, no synergy was 1 observed when these translation inhibitors were used in combination with docetaxel ( Fig S7A) . We 2 also confirmed the cytotoxic effect of these two flavaglines on parental, docetaxel-and cabazitaxel-3 resistant cell lines, as shown by the induction of PARP cleavage (Fig 6C) . Importantly, FL3 and FL23
4
did not lead to apoptosis of RPE-1 cells (Fig 6C) , reinforcing the interest of targeting eIF4A to abrogate 5 taxane resistance in prostate cancer. 
26
limited set of pro-oncogenic mRNA transcripts (Bhat et al, 2015) . We show that the FKBP7-eIF4G 27 interaction led to an increased level of eIF4G which is normally a limiting factor of this process.
28
Through its chaperone activity, FKBP7 may protect eIF4G from degradation by preventing its ubiquitin-29 mediated proteolysis. This function could also be achieved by the Hsp90 and Hsp70 proteins which are only associated with FKBP7 in resistant cells (Table S3) . Such a process has been described for (Fig 7) . 
12
Hyperactivity of the Akt-mTOR pathway was observed in many cancers including prostate cancer 13 (Bitting & Armstrong, 2013) and this pathway was shown to be implicated in chemoresistance in 14 prostate cancer (Vidal et al, 2015) . In that case, the chemoresistance should be alleviated with 
20
As we have shown that FKBP7 has an important role in survival networks that protect cancer cells (Bhat et al, 2015) . We first tested silvestrol which inhibits eiF4A and was shown to 6 provide therapeutic benefits in prostate cancer xenografts (Cencic et al, 2009) . Unfortunately, silvestrol 7 shows no obvious efficacy towards docetaxel-resistant IGR-CaP1 cell proliferation, which could be 
28
For all the resistant cell lines, Log10 (ratios) were computed against the sensitive cell line. In order to 29 select relevant genes, we combined three different strategies. First, gene permanently overexpressed (or under-expressed), from the first dose, in all the resistant cell lines, were tested using multiple t- over the increasing doses were tested using 5-parameter logistic regressions (Giraldo et al, 2002) .
5
The decision rule combined an absolute fold change of at least 2 between the lower and the upper 6 asymptotes, and an adjusted p-value ≤1e-3, representing the quality of the correlation between the 
Data correction and scoring were performed as described previously (Mahmood et al, 2014) . Briefly, 6 data were first transformed with log or logit functions. B-score normalization was then applied to each 
12
'hit', if the RZ-score for at least two of four siRNAs was > 2 or < -2 in at least two of three replicates.
13
Thirty-four hits were thus selected.
15
Immunohistochemistry
16
The prostate tissue samples used for TMA were obtained from the Vancouver Prostate Centre Tissue
17
Bank with written informed patients' consent, clinical information and institutional study approval, and 18 were previously reported. The H&E slides were reviewed and the desired areas were marked on them 
13
Reverse transfection was performed using lipofectamine RNAiMax (Thermo Fisher Scientific). Cell were sacrificed, and tumors were excised and measured.
11
In vivo shRNA knockdown
12
Two distinct shRNAs targeting FKBP7 (shFK-1 and shFK-2) were engineered and packaged using the 
23
Immunoprecipitation of endogenous FKBP7
24
IGR-CaP1-Dtx-R and RPE-1 cells were grown in 4 T150 flasks and harvested at ~80% confluency.
25
Cells were lysed in an optimized buffer (120mM NaCl, 20mM Hepes, 1mM EDTA, 5% glycerol, 0.5% 
15
The minimal peptide length was specified to be 6 amino acids. The data were searched against a
16
decoy database, and the false discovery rate was set to 1% at the peptide level. FKBP7 interactors
17
were selected when proteins were only identified in the FKBP7 immunoprecipitation as compared to
18
IgG control or when proteins were enriched at least three fold in the specific immunoprecipitation as 
14
Master Mix on Viia7 System (Applied Biosystems). The ∆∆CT method was used to quantify transcripts.
16
Western Blot analysis
17
Immunoblots were performed from whole cell lysate prepared with RIPA buffer complemented with 
21
(Sigma-Aldrich) and HSC70 (Santa-Cruz Biotechnology) were used as a loading control. Immunoblot
22
analyses were performed using the enhanced chemoluminescence-based detection kit (Pierce).
24
Proximity ligation assay
25
Interactions between eIF4G and FKBP7 (FKBP7-eIF4G) and eiF4E and eiF4G (eiF4E-eiF4G) were 26 detected by in situ proximity ligation assay (PLA) (Duolink, Sigma-Aldrich). Cells were fixed with 27 paraformaldehyde, permeabilized and the PLA protocol was followed according to the manufacturers' 28 instructions (Olink Bioscience). After blocking, the primary antibodies were incubated 1h at 37°C. For 
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